Holen Sie sich die Stockscreener-App
52.13
0.27%
-0.14
Handel nachbörslich:
52.38
0.25
+0.48%
Schlusskurs vom Vortag:
$52.27
Offen:
$52.16
24-Stunden-Volumen:
1.88M
Relative Volume:
0.71
Marktkapitalisierung:
$132.13B
Einnahmen:
$48.62B
Nettoeinkommen (Verlust:
$6.80B
KGV:
18.59
EPS:
2.8038
Netto-Cashflow:
$7.62B
1W Leistung:
-3.64%
1M Leistung:
+4.55%
6M Leistung:
+1.58%
1J Leistung:
+4.05%
1-Tages-Spanne:
$51.73
$52.22
1-Wochen-Bereich:
$51.66
$55.73
52-Wochen-Spanne:
$45.80
$60.12
Sanofi Adr Stock (SNY) Company Profile
Vergleichen Sie SNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
52.13 | 132.13B | 48.62B | 6.80B | 7.62B | 2.8038 |
|
LLY
Lilly Eli Co
|
751.45 | 681.85B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.66 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
185.58 | 342.01B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
64.85 | 291.20B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.13 | 219.89B | 53.22B | 12.86B | 14.85B | 6.39 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-03-21 | Eingeleitet | Goldman | Neutral |
| 2025-01-30 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-07-26 | Bestätigt | Argus | Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2023-12-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-10-30 | Herabstufung | Stifel | Buy → Hold |
| 2023-09-06 | Hochstufung | Berenberg | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-28 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-03-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-12-13 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-08-12 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-08-09 | Herabstufung | UBS | Buy → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Sell |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-03-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-03-11 | Hochstufung | Goldman | Neutral → Buy |
| 2020-02-11 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-01-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-09-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | Eingeleitet | Bernstein | Outperform |
| 2019-08-14 | Hochstufung | UBS | Neutral → Buy |
| 2018-12-11 | Hochstufung | Jefferies | Hold → Buy |
| 2018-11-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-03-23 | Hochstufung | Liberum | Hold → Buy |
| 2018-01-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2017-12-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2017-08-30 | Hochstufung | HSBC Securities | Reduce → Hold |
Alle ansehen
Sanofi Adr Aktie (SNY) Neueste Nachrichten
Metric Deep Dive: Understanding Sanofi ADR (SNY) Through its Ratios - DWinneX
Sanofi: Investițiile în prevenție susțin sănătatea și competitivitatea Europei - GlobeNewswire Inc.
iRhythm Technologies Inc (IRTC) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
WLK’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
BIDU’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
A Tale of Resilience: Sanofi ADR Amid Stock Market Turbulence - investchronicle.com
Company’s Banking Stock: Dissecting a 40.08% Quarterly Revenue Decline Amid Growth - investchronicle.com
Trip.com Group Ltd ADR (TCOM) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
CYTK’s 2023 Market Dance: Down -21.41% – Time to Invest? - investchronicle.com
CIG’s Market Whiplash: 8.19% YTD Rise, 9.30% Rise in 30 Days - investchronicle.com
LX’s 2023 Market Dance: Up 43.28% – Time to Invest? - investchronicle.com
Terex Corp (TEX) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Behind Cytosorbents Corp’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
Companhia Siderurgica Nacional ADR (SID) Stock: From Low to High in 52 Weeks - investchronicle.com
The Future of EVgo Inc: Analyzing EVGO - investchronicle.com
NVS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Unilever plc ADR: Rising -3.90% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Adaptive Biotechnologies Corp (ADPT) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Futu Holdings Ltd ADR (FUTU) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
Stryker Corp (SYK) Stock: Navigating a Year of Volatility - investchronicle.com
Viking Holdings Ltd’s Banking’s 100-Day Moving Average at 44.43: Will the Stock Break Through? - investchronicle.com
Sandisk Corp (SNDK) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
LSCC: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
LATAM Airlines Group S.A. ADR’s Banking’s 100-Day Moving Average at 29.99: Will the Stock Break Through? - investchronicle.com
DUOL’s 2023 Market Dance: Up 43.43% – Time to Invest? - investchronicle.com
PLRZ Stock: Exploring Polyrizon Ltd’s Growth - investchronicle.com
Sumitomo Mitsui Financial Group Inc ADR (SMFG) Stock: A Year of Market Movement, Down and Up - investchronicle.com
Vipshop Holdings Ltd ADR Inc. (VIPS) Price Performance: The Role of Supply and Demand - investchronicle.com
The Significance of Moving Averages in Live Nation Entertainment Inc Inc. (LYV) Price Performance - investchronicle.com
APG’s Stochastic Averages Dip: Analyzing APi Group Corporation’s Stock Performance - investchronicle.com
CNMD’s 52-Week Rollercoaster: From $46.00 to $78.58 – What’s Next for Investors? - investchronicle.com
AngloGold Ashanti Plc (AU) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
UDMY: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Hologic, Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
Viavi Solutions Inc (VIAV) Stock: From Low to High in 52 Weeks - investchronicle.com
PRU’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
ModivCare Inc (MODV) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Uncovering the Potential of Idexx Laboratories, Inc (IDXX) Stock - investchronicle.com
Mimedx Group Inc (MDXG) Stock: A Year of Market Fluctuations - investchronicle.com
AMRX’s Financial Health: Exploring Amneal Pharmaceuticals Inc’s Debt-to-Equity Ratio of 1.79 - investchronicle.com
Childrens Place Inc Inc. (PLCE) Price Performance: A Fundamental Analysis Perspective - investchronicle.com
Vine Hill Capital Investment Corp (VCIC) Stock: A Year of Declines and Increases - investchronicle.com
Leonardo DRS Inc (DRS) Stock: Navigating Drops and Gains - investchronicle.com
Stocks With Rising Relative Price Strength: Smith & Nephew ADR - inkl
Stocks With Rising Relative Strength: Belden - inkl
ZTO Express [Cayman] Inc ADR [ZTO] is -2.81% lower this YTD. Is it still time to buy? - dbtnews.com
For Sanofi ADR [SNY], Analyst sees a rise to $65. What next? - dbtnews.com
MaxLinear Inc [MXL] Stock trading around $9.65 per share: What’s Next? - dbtnews.com
European Drug Giants Report. But Only One Beats Sales Views. - Investor's Business Daily
There is no doubt that Sanofi ADR (SNY) ticks all the boxes. - Sete News
Sanofi ADR earnings beat by $0.12, revenue fell short of estimates - Investing.com Canada
Finanzdaten der Sanofi Adr-Aktie (SNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.75%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):